

Surrey and North West Sussex Area Prescribing Committee (APC)

Policy Statement	Liothyronine (T3) in the management of hypothyroid states occurring in the treatment of thyrotoxicosis.
Policy Number	APC 409-2019 (replaces PCN191-2016)
Date of Issue	June 2019
Review Date	June 2022 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
Recommendations: The Surrey and North West Sussex Area APC recommends the use of liothyronine (T3) in the management of hypothyroid states occurring in the treatment of thyrotoxicosis and is considered as RED on the traffic light system.	
Key Considerations: <ul style="list-style-type: none"> • These patients will be treated by specialists in secondary or tertiary care. • Liothyronine sodium can be used also in the treatment of thyrotoxicosis as an adjunct to carbimazole to prevent sub-clinical hypothyroidism developing during treatment. 	
Date taken to Surrey & North West Sussex Area Prescribing Committee (APC)	5 th June 2019
Agreed by APC members	21 st June 2019

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG